This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Marches, R. Articles by Uhr, J. W. Search for Related Content PubMed PubMed Citation Articles by Marches, R. Articles by Uhr, J. W.

Cancer Dormancy: Role of Cyclin-dependent Kinase Inhibitors in Induction of Cell Cycle Arrest Mediated via Membrane IgM^1,2,

Cancer Immunobiology Center and Departments of Microbiology [R. M., J. W. U.] and Pathology [R. H. S.], University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75235-8576

Anti-idiotype (anti-Id) antibody can induce tumor dormancy in a murine B lymphoma, BCL₁, by its ability to induce cell cycle arrest and apoptosis (negative signaling). In human B lymphoma, there is accumulating evidence that the antitumor effect of anti-Id or several other B cell-reactive antibodies relates to their ability to act as agonists rather than conventional effector antibodies. In this study, we sought to elucidate the role of cyclins, cyclin-dependent kinases (CDKs), and their inhibitors in anti-IgM-induced cell cycle arrest to better understand the mechanisms underlying cancer dormancy. To accomplish this, we have performed in vitro studies with a human lymphoma cell line (Daudi) because its response to anti-Id (or anti-IgM) is similar to that of a BCL₁ cell line, more reagents are available, and the results would be particularly pertinent to therapy of human B cell lymphomas. Our results show that cross-linking of membrane IgM on Daudi cells induces an arrest late in G₁ and prevents pRb from becoming phosphorylated. The G₁ arrest is correlated with an induction of the CDK inhibitor p21 and reduced CDK2 activity, although the level of CDK2 protein was not changed. Coprecipitation of CDK2 with p21 in anti-IgM-treated cells and the unchanged level of cyclin E suggest that p21 is responsible for the reduction of CDK2 activity and therefore blockade of the cell cycle. The induction of p21 was not accompanied by changes in p53 levels. As a result of the G₁ block, cyclin A levels sharply declined by 24 h after anti-IgM treatment. There was no evidence for involvement of CDK4 or CDK6 in the blockade.

These results provide evidence that membrane IgM cross-linking on Daudi cells induces expression of p21 and a subsequent inhibition of the cyclin E-CDK2 kinase complex resulting in a block to pRb phosphorylation and cell cycle arrest late in G₁.

¹ This work was supported by NIH Grant 5-RO1-CA28149 and ACS Grant RPG-95-079-03-CCG.

² This is paper no. 6 in a series.

³ To whom requests for reprints should be addressed, at Cancer Immunobiology Center, University of Texas Southwestern Medical Center at Dallas, 6000 Harry Hines Boulevard, Dallas, TX 75235-8576.

Received 8/19/97. Accepted 12/16/97.

This article has been cited by other articles:

				D. Stefanello, S. Romussi, P. Signorelli, M. Caniatti, M. DiGiancamillo, P. Roccabianca, and G. Avallone Primary Osseous Melanoma in the Tibia of a Dog J. Am. Anim. Hosp. Assoc., May 1, 2008; 44(3): 139 - 143. [Abstract] [Full Text] [PDF]

				P. W. Chen, T. Uno, and B. R. Ksander Tumor Escape Mutants Develop within an Immune-Privileged Environment in the Absence of T Cell Selection J. Immunol., July 1, 2006; 177(1): 162 - 168. [Abstract] [Full Text] [PDF]

				N. Savelyeva, C. A. King, E. S. Vitetta, and F. K. Stevenson Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help PNAS, August 2, 2005; 102(31): 10987 - 10992. [Abstract] [Full Text] [PDF]

				S. Meng, D. Tripathy, E. P. Frenkel, S. Shete, E. Z. Naftalis, J. F. Huth, P. D. Beitsch, M. Leitch, S. Hoover, D. Euhus, et al. Circulating Tumor Cells in Patients with Breast Cancer Dormancy Clin. Cancer Res., December 15, 2004; 10(24): 8152 - 8162. [Abstract] [Full Text] [PDF]

				A. Saudemont and B. Quesnel In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-H1 and B7.1 expression and resist CTL-mediated lysis Blood, October 1, 2004; 104(7): 2124 - 2133. [Abstract] [Full Text] [PDF]

				R. Marches, E. S. Vitetta, and J. W. Uhr A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas PNAS, February 22, 2001; (2001) 61028998. [Abstract] [Full Text]

				J. Honeychurch, A. L. Tutt, T. Valerius, I. A. F. M. Heijnen, J. G. J. Van de Winkel, and M. J. Glennie Therapeutic efficacy of Fcgamma RI/CD64-directed bispecific antibodies in B-cell lymphoma Blood, November 15, 2000; 96(10): 3544 - 3552. [Abstract] [Full Text] [PDF]

				D. Chen, V. Heath, A. O'Garra, J. Johnston, and M. McMahon Sustained Activation of the Raf-MEK-ERK Pathway Elicits Cytokine Unresponsiveness in T Cells J. Immunol., December 1, 1999; 163(11): 5796 - 5805. [Abstract] [Full Text] [PDF]

				J. A. Aguirre Ghiso, K. Kovalski, and L. Ossowski Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling J. Cell Biol., October 4, 1999; 147(1): 89 - 104. [Abstract] [Full Text] [PDF]

				R. Marches, R. Hsueh, and J. W. Uhr Cancer dormancy and cell signaling: Induction of p21waf1 initiated by membrane IgM engagement increases survival of B lymphoma cells PNAS, July 20, 1999; 96(15): 8711 - 8715. [Abstract] [Full Text] [PDF]

				R. DONNELLAN and R. CHETTY Cyclin E in human cancers FASEB J, May 1, 1999; 13(8): 773 - 780. [Abstract] [Full Text]

				A. Kramer, S. Horner, A. Willer, S. Fruehauf, A. Hochhaus, M. Hallek, and R. Hehlmann Adhesion to fibronectin stimulates proliferation of wild-type and bcr/abl-transfected murine hematopoietic cells PNAS, March 2, 1999; 96(5): 2087 - 2092. [Abstract] [Full Text] [PDF]

				R. Marches, E. S. Vitetta, and J. W. Uhr A role for intracellular pH in membrane IgM-mediated cell death of human B lymphomas PNAS, March 13, 2001; 98(6): 3434 - 3439. [Abstract] [Full Text] [PDF]